Skip to content
Screener

Nektar Therapeutics NKTR Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Amgen logo
AmgenAMGN
$00.0%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$0
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0.010.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$00.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
CTO
Citius Oncology, Inc.CTOR

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.58B+551%
Enterprise value$2.66B+445%
P/S46.5×+41.1×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at March 31, 2026 or December 31, 2025, respectively
Common stock, $0.0001 par value; 390,000,000 shares authorized; 29,472,092 shares and 20,378,832 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively32
Capital in excess of par value4,382,4373,850,099
Accumulated other comprehensive income (loss)(1,034)17
Accumulated deficit(3,805,190)(3,760,286)
Total stockholders’ equity576,21689,832

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's common stock, par value (in dollars per share)?
Nektar Therapeutics (NKTR) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has Nektar Therapeutics's common stock, par value (in dollars per share) changed year-over-year?
Nektar Therapeutics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Nektar Therapeutics's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Nektar Therapeutics's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Ask your AI about Nektar Therapeutics's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude